Kornimate/medical-research-clean huggingface dataset:
treatment of urinary incontinence in men after prostatectomy with autologous adipose-derived mesenchymal stem cells

Conditions: Urinary Incontinence

Summary: treatment of patients with urinary incontinence after prostatectomy using injection of autologous adipose-derived mesenchymal stem cells mixed with collagen gel

during the implementation of the project, it is planned to develop a method for the treatment of men urinary incontinence caused by prostatectomy using injection of autologous adipose-derived mesenchymal stem cells mixed with collagen. the positive outlook for the effectiveness of mscs is due to the following: * the ability of mscs to stimulate tissue regeneration * positive results of preclinical studies of the method of treatment of urinary incontinence in animals. in study planing to include 5 patients. mscs will be isolated from adipose tissue, cultured and then transplanted back to the periurethral area by five point injection in rhabdosphincter and submucosal space of urethra using the cystourethroscope. for injection in submucosal space mscs (20\*10\^6 cells) will be mixed with collagen solution (3,5% w\|w). follow up patients monitoring will occur at 1，3，6 and 12 months after injection.

Eligibility criteria:
inclusion criteria: * urinary incontinence * absence of acute inflammatory manifestations in the genitourinary system * period after prostatectomy is at least 12 months exclusion criteria: * urethral or bladder malformations * acute and chronic infectious diseases: hiv, viral hepatitis, tuberculosis * mental disorders

Keywords: urinary incontinence prostatectomy
dp vs dfr for management of geriatric distal femur fractures.

Conditions: Distal Femur Fracture; Geriatrics

Summary: the aim of this study was to compare the functional and radiological outcomes of fixation by using double plating technique versus replacement using distal femur tumor prothesis as a primary management for the distal femoral fractures in geriatric patients. the hypothesis was that the distal femoral replacement will yield better functional outcome and earlier rehabilitation and return to pre-injury level of activity.

geriatric distal femoral fractures represent a major challenge for the orthopedic surgeons, to the present days still there is no definite algorithm or specific guidelines that can be used accurately in the management of these fractures. unlike hip fractures however, there is no widely accepted treatment algorithm or standard of care. the surgical treatment of distal femoral fractures depends on both patient and fracture characteristics. options include conservative treatment, open reduction internal fixation, intramedullary nails, or recently distal femoral replacement. there is currently a move towards distal femoral replacement (dfr) for these complex fractures which has the potential benefit of allowing early weight bearing, and therefore aiming to prevent complications associated with immobility and non-union. using distal femoral replacement had yield good results in small case series, as it allows immediate full weightbearing, eliminate the risk of nonunion and may provide greater satisfaction scores. however, dfr has its own risks, most notably deep infection, and loosening. while a dfr is more costly compared with fixation plates and nails, the initial increased cost may be outweighed by faster rehabilitation and return to the patient's usual place of residence. in the study, the investigators are aiming to compare the functional and radiological outcomes of fixation by using double plating technique versus replacement as a primary management for the geriatric distal femoral fractures.

Eligibility criteria:
inclusion criteria: * ao 33 a3 and 33 c fractures * age group ≥ 60 years * closed fractures * neurovascular intact exclusion criteria: * open fractures * non ambulant patients * patients with peripheral neurovascular diseases * peri-prosthetic fractures * associated other orthopedic injuries * poly-traumatized patients * pathological fractures

Keywords: distal femoral fractures double plating distal femoral replacement geriatrics
pet-guided external beam radiotherapy in differentiated thyroid cancer

Conditions: Differentiated Thyroid Cancer

Summary: description of the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.

the role of post-operative external beam radiotherapy (ebrt) in differentiated thyroid cancer is still discussed considering the low clinical aggressiveness and the availability of ablative 131iodine therapy. however, there is a subgroup of tumors which lose the ability to capture iodine over time. this study wants to describe the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.

Eligibility criteria:
inclusion criteria: * detectable thyroglobulin (tg), * negative post-metabolic radiotherapy whole body scintigraphy, * no surgical indications. exclusion criteria: * prior radiotherapy in the head and neck area * pregnancy
efficacy of zinc in the treatment of bronchiolitis and prevention of wheezing respiratory illness in children less than two years old

Conditions: Bronchiolitis

Summary: 1. bronchiolitis is a leading cause of morbidity and mortality in children. it is an acute, infectious illness of the lower respiratory tract resulting in obstruction of the bronchioles. the etiology is viral in the majority of the cases and rsv is the most commonly isolated agent. the disease is more common in younger children under 2 years of age. children often receive unnecessary antibiotics and often require hospitalization. an episode of bronchiolitis can be followed by recurrent wheezing episodes. rsv bronchiolitis in the first year of life is one of the most important risk factors for the subsequent development of asthma in both developed and developing countries. thus, bronchiolitis is a global public health problem. zinc supplementation has been shown to be effective in both preventing and treating pneumonia. however, no study has particularly examined the effect of zinc on ari associated with wheezing. this study aims to investigate whether zinc (20 mg/day) reduces1. the duration of bronchiolitis in children.2. the severity of bronchiolitis in children.3. the rate of hospitalization for bronchiolitis.3. future episodes of wheezing in children.


Eligibility criteria:
inclusion criteria: children 2 months to 23 months old at the time of clinical diagnosis· episode of wheezing for the first time written consent· who do not require hospitalization at the time of diagnosis exclusion criteria: history of asthma chronic cardiac or respiratory disease (e.g.cyanotic heart disease -asd) history of previous wheezing or bronchodilator therapy gestational age at birth \<34 weeks suspected tuberculosis, active measles any illness (severe malnutrition, sepsis, meningitis) that requires hospitalisation who had zinc/placebo supplements during this study· h/o zinc intake within last 3 months· whose caretakers withhold consent

Keywords: zinc treatment bronchiolitis wheezing children aged 2 months to 23 months diagnosed case of acute bronchiolitis
cart19 in adult patients with minimal residual disease during upfront treatment for all

Conditions: Leukemia, Acute Lymphoblastic

Summary: this is a single center, single arm, open-label phase 2 study to determine the efficacy of autologous t cells expressing cd19 chimeric antigen receptors expressing tandem tcrζ and 4-1bb (tcrζ/4-1bb) co-stimulatory domains (referred to as "cart19" cells) in adults with minimal residual disease (mrd) during upfront treatment for cd19+ acute lymphoblastic leukemia.


Eligibility criteria:
inclusion criteria: 1. patients with cd19+, b cell acute lymphoblastic leukemia (b-all) who have 0.01%≤mrd\<10% during upfront treatment 2. patients must be within 18 months of initial all diagnosis 3. age ≥18 years 4. adequate organ function defined as: 1. creatinine ≤ grade 2 2. alt/ast ≤3x upper limit of normal range for age 3. direct bilirubin ≤2.0 mg/dl 4. adequate pulmonary function defined as ≤ grade 2 dyspnea and ≤ grade 2 hypoxia 5. cardiac left ventricle ejection fraction (lvef) ≥ 40% confirmed by echo/muga 5. patients with cns3 disease will be eligible if cns disease is responsive to therapy. 6. expression of cd19 on leukemic blasts demonstrated by flow cytometry or immunohistochemistry of bone marrow or peripheral blood 7. adequate performance status defined as ecog performance status 0 or 1 8. provides written informed consent 9. subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol exclusion criteria: 1. active, uncontrolled infection 2. active hepatitis b or hepatitis c 3. hiv infection 4. class iii/iv cardiovascular disability according to the new york heart association classification (see appendix 2) 5. subjects with clinically apparent arrhythmia or arrhythmias who are not stable on medical management within two weeks of enrollment. 6. pregnant or nursing (lactating) women 7. patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to leukemia or previous leukemia treatment.
follow-up after endovascular repair of abdominal aortic aneurysm

Conditions: Abdominal Aortic Aneurysm

Summary: to collect and analyze clinical follow-up data which can be used to assess the safety, efficacy, and durability of endovascular aaa repair with zenith and chuter-gianturco stent-grafts.

we propose to analyze the data collected for clinical purposes in 453 patients who already underwent endovascular aaa repair at ucsf and sfva, and others who will undergo this operation in the future. most of these patients have now passed the 2-year follow-up required by the original protocol, all continue to be followed for clinical purposes, using the same studies, the same data forms and the same schedule as before, because studies of various devices of this type have shown that the potential for late problems requires continuing scrutiny of stent-graft structure and function, as a basis for timely re-intervention.

Eligibility criteria:
inclusion criteria: * aaa with diameter \> 4 cm or aaa with a history of growth \> 0.5 cm per year * treatment of aaa with zenith stent-graft exclusion criteria: * pregnant * life expectancy less than two years * less than 18 years of age * unwilling to comply with clinical follow-up schedule * inability or refusal to give informed consent

Keywords: stent-graft aaa abdominal aortic anuerysm zenith endovascular treatment with zenith aortic stent-graft for repair abdominal aortic aneurysm
nurse parental support using a mobile app in symptom management for cmc

Conditions: Child With Cancer; Muscular Atrophy; Child With Cerebral Palsy; Child With Medical Complexity

Summary: parents of children with medical complexity (cmc) are suffering from high level of stress. these cmc get multisystem diseases, including severe neurologic conditions or cancer, resulting in potential premature death. they experience one or more physical and psychological symptoms at one time, which seriously affect their quality of life and increase their health services utilization. parents may lack confidence in their abilities when managing their child's symptoms. literature suggested that increasing parental self-efficacy in managing their child's symptoms could improve child's health status. home-based nursing services for the cmc and parents are available in hong kong. however, the service faces challenges because of serious nursing workforce shortage and the recent coronavirus pandemic. nurse parental support in symptom management using a proactive mobile health app is an alternative method considered more feasible to continue home-based support for the cmc and parents. this proposed rct will test the effects of a nurse-led mobile app for enhancing parental self-efficacy in symptom management for cmc. a repeated-measures, two-group design will be used to evaluate the effects between intervention and wait-listed control groups by comparing the study group receiving nurse support using a mobile app, and the wait-listed control group receiving usual community care for 96 randomly selected parents over a three-month follow-up. primary outcome is parental self-efficacy. secondary outcomes include children's symptom burden and health services utilization. these factors will be measured before intervention, immediately after intervention and three-month after intervention. the effectiveness of the intervention will be evaluated by comparing the primary outcome at three-month after intervention across the two study groups using ancova with control for the pre-test value of parental self-efficacy. generalized estimating equation will be used to address secondary objectives regarding the effectiveness of the mobile app as compared to the control on secondary outcomes from t1 to t3 with appropriate link function. it is hypothesized that nurse support using the mobile app is more effective than usual community care in enhancing parental self-efficacy in symptom management for their cmc at three-month after intervention.


Eligibility criteria:
inclusion criteria: the eligible criteria for parents are: 1. parent of a child with medical complexity aged 2-18 2. having a smartphone 3. able to communicate in chinese and read chinese 4. living with his/her child at home. exclusion criteria: the exclusion criteria for parents are 1. a reported mental health disorder 2. engaging in other structured programs related to symptom management 3) living in an area with no internet coverage.

Keywords: child with medical complexity child with cancer parental self-efficacy mobile health application symptom management
effects of peppermint oil in mild-moderate hypertension.

Conditions: Hypertension

Summary: cardiovascular and associated hypertensive diseases are the leading health burden and cause of mortality worldwide; therefore, the necessity for effective interventions is paramount. dietary interventions to improve cardiovascular health are highly sought after as they possess less risk and financial burden than pharmacological drugs. our previous randomized trial has shown that oral peppermint can improving systolic blood pressure and other cardiovascular/ blood lipids in healthy individuals. however, to date, no research has explored this using a placebo randomized intervention in patients with hypertension. therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in participants with mild-moderate hypertension.


Eligibility criteria:
inclusion criteria: 1. aged from 18-65 years 2. systolic blood pressure 120 to 139 mmhg 3. not taking prescribed medicine for blood pressure management 4. have the ability to complete written questionnaires independently 5. able to provide informed consent exclusion criteria: 1. diagnosed with diabetes mellitus and/ or coronary heart disease 2. pregnant and lactating women 3. allergy to peppermint 4. habitual consumption of peppermint products 5. regular consumption of antioxidant supplements (5) body mass index larger than 40.0 kg/m2 (6) current enrolment in other clinical trials of other external therapies
a phase 2 study of an oral vitamin d compound (dp001) in secondary hyperparathyroidism in patients on hemodialysis

Conditions: Hyperparathyroidism, Secondary; Kidney Failure, Chronic

Summary: the goal of this study is to test a new vitamin d compound for its ability to reduce parathyroid hormone levels in patients who are on hemodialysis.

this is a randomized, double-blind, placebo-controlled study of the vitamin d analog 2-methylene-19-nor-20s-1α,25-dihydroxyvitamin d3 (dp001) in patients with end-stage renal disease (esrd). the effect of 12 weeks of oral administration of dp001 on serum parathyroid hormone (pth) levels will be evaluated in esrd patients who have secondary hyperparathyroidism.

Eligibility criteria:
inclusion criteria: * men and non-pregnant women ≥18 years of age * patient is diagnosed with esrd and must be on hemodialysis 3 times per week for at least 3 months prior to screening phase * patient is currently being treated with pharmaceutical vitamin d for the treatment of secondary hyperparathyroidism * serum ipth value ≤500 pg/ml at first screening visit * total serum calcium (corrected for albumin) ≤10.5 mg/dl at first screening visit * serum phosphorus ≤7.0 mg/dl at first screening visit exclusion criteria: * currently taking any of the following: drugs affecting vitamin d metabolism, digitalis, glucocorticoids, cyclosporine or other immunosuppressants, aluminum-based phosphate binders * a daily intake \>4000 iu vitamin d (d3 + d2) * any investigational drug use within 10 half-lives of the drug (or within the previous 30 days if the half-life of the drug is unknown) * history of any of the following: ventricular dysrhythmias, severe congestive heart failure, angina pectoris, myocardial infarction, coronary angioplasty, coronary artery bypass grafting, multiple myeloma, calciphylaxis, active malignancy, end-stage liver disease, active infections, clinically significant renal/urinary tract stones, sarcoidosis, tuberculosis, parathyroidectomy * major surgery within the past 3 months

Keywords: hemodialysis
pharmacogenetic panel to prevent adverse drug reactions in daily primary care practice:

Conditions: Pharmacogenomic Drug Interaction; Side Effect of Drug; Ineffective Drug Action; Drug Metabolism, Poor, CYP2D6-Related; Drug Metabolism, Poor, CYP2C19-Related

Summary: the purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (pgx) testing of a panel of clinically relevant pgx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated adrs which are causally related to the initial drug of inclusion (referred to as 'index drug').


Eligibility criteria:
inclusion criteria: * inclusion criteria: in order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. subject must be ≥ 18 years old 2. subject must receive a 1st prescription (meaning no known prescription for this drug in the preceding 12 months) for a drug included in table 1, which is prescribed to them in routine primary care. 3. subject is able and willing to take part and willing to be followed up on for 48 weeks 4. subject is able to donate saliva 5. subject has signed informed consent 6. subject meets requirement for computer access implying computer literacy as measured by active use of the patient portal or their email exclusion criteria: 1. for the investigational arm only: previous (direct-to-consumer, or clinical) pharmacogenomic testing that includes any of the genes included in the focused pharmacogenomics panel 2. pregnant or lactating (to be verbally confirmed with the patient) 3. life expectancy estimated to be less than three months as determined by patient receiving hospice care 4. duration of index drug total treatment length is planned to be less than seven consecutive days. 5. current inpatients 6. unable to consent to the study 7. unwilling to take part 8. subject has no permanent address 9. subject has no current primary care provider 10. subject is, in the opinion of the study coordinator after discussion with participating clinician/pharmacist/investigator, not suitable to participate in the study 11. patient has a diagnosis of stage 4 or 5 chronic kidney disease (ckd) or is receiving dialysis 12. patients with advanced liver failure (stage child-pugh c) or a diagnosis of liver cirrhosis 13. history of a liver transplant or an allogeneic hematopoietic stem cell transplant 14. dna sample collected that requires retesting in the event that dna collected was not sufficient for testing as determined by the laboratory

Keywords: pharmacogenomics pgx cpic primary care drug metabolism side effects ineffectiveness prepare-mayo
stromal vascular fraction cell therapy to improve the repair of rotator cuff tears

Conditions: Rotator Cuff Tear; Muscle Atrophy; Tendon Tear

Summary: rotator cuff disease is one of the most prevalent musculoskeletal conditions across the world. patients with chronic rotator cuff tears often have substantial muscle atrophy and fatty infiltration. surgical repair of the tear does not reverse the atrophy, and many patients continue to experience weakness, pain, and a persistent reduction in the quality of life. an important limitation in our ability to successfully rehabilitate these injuries postoperatively and return patients to normal function has to do with the poor quality of the muscle and tendon after rotator cuff repair. the stromal vascular fraction (svf) of subcutaneous adipose tissue is highly enriched with cells (svfcs) that can both directly participate in tissue regeneration by differentiating into myogenic and tenogenic cells, and indirectly by secreting growth factors and small molecules which activate pathways associated with healthy tissue regeneration. high numbers of autologous svfcs can be isolated using the cost-effective, intraoperative icellator (tissue genesis, honolulu, hi) point-of-care system. this clinical trial will be determine if the use of svfcs can enhance outcomes for patients who are undergoing surgical repair of a torn supraspinatus rotator cuff.


Eligibility criteria:
inclusion criteria: * males and females * age 45-65 years old at the time of enrollment * full-thickness supraspinatus tendon tear with endon retraction ≤ 3 cm * magnetic resonance imaging goutallier score ≤ grade 2 * completed at least 6 weeks of standard physical therapy but continue to have pain and limited function (failed physical therapy) * sufficient subcutaneous abdominal adipose tissue to allow the recovery of 60-120cc of lipoaspirate * must pass standard of care blood work screening exclusion criteria: * any tears of any cuff tendon other than the supraspinatus * magnetic resonance imaging goutallier scores ≥ 3 * frank signs of glenohumeral osteoarthritis on magnetic resonance imaging * a history of previous rotator cuff repair * a history of upper extremity fracture or other moderate to severe upper extremity trauma * a bmi \ 35 * pregnant or breast feeding * premenopausal women who are not using contraception * previous abdominal liposuction or any major open abdominal surgery * type i or type ii diabetes, or glycated hemoglobin (hemoglobin a1c) values \> 6.5 or other metabolic disorders * hypercholesterolemia (total cholesterol ≥240mg/dl) * history of cancer * autoimmune disorder or hiv+ status * use of nicotine products * have any other history of major medical illness, disease or other relevant orthopaedic disability * who do not speak english * liodcaine allergy
effects of foot exercises and hydrotherapy on pedal edema & lower extremity function

Conditions: Pregnancy Related

Summary: to determine the effects of foot exercises with and without hydrotherapy on pedal edema \& lower extremity function in antenatal women.


Eligibility criteria:
inclusion criteria: * normal singleton pregnancy * gestational age 30-40 weeks * pitting edema in feet exclusion criteria: * presence of any under lying disease e.g. * diabetes, * hypertension, * high risk pregnancy * any wound or skin lesion

Keywords: foot exercises hydrotherapy pedal edema lower extremity antenatal women